784 results about "Serum protein" patented technology

The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising VHHs in biological circulatory systems.

A method for quantitating vitamin D metabolites directly in blood plasma or serum, without the need for prior purification of the vitamin D metabolites, comprising a digestion of the serum proteins with a serine protease such as proteinase K and sequence of steps for inhibiting the proteinase K activity in the competitive binding analysis. The advantages of this method are its high accuracy over the whole range of physiologically relevant values and that it can be easily adapted for a fully automated analysis of serum and plasma samples.

Size-selective hemocompatible porous polymeric adsorbents are provided with a pore structure capable of excluding molecules larger than 50,000 Daltons, but with a pore system that allows good ingress and egress of molecules smaller than 35,000 Daltons. The pore system in these porous polymeric adsorbents is controlled by the method of synthesis so that 98% of the total pore volume is located in pores smaller than 300 Angstroms (Å) in diameter with a working pore size range within 100 to 300 Å in diameter. The porous polymeric adsorbents of this invention are very selective for extracting midsize proteins, such as cytokines and β₂-microglobulin, from blood and other physiologic fluids while keeping the components required for good health such as cells, platelets, albumin, hemoglobin, fibrinogen, and other serum proteins intact.

The invention provides tools for management of patients diagnosed with ankylosing spondylitis and prior to the initiation of therapy with an anti-TNFalpha agent. The tools are specific markers and algorithms of predicting response to therapy based on standard clinical primary and secondary end-points using serum marker concentrations. In one embodiment the baseline level of leptin or osteocalcin is used to predict the response at Week 14 after the initiation of therapy. In another embodiment, the change in a serum protein biomarker after 4 weeks of therapy is used such as complement component 3.

The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising VHHs in biological circulatory systems.

The invention relates to a preparation method of a protein magnetic imprinting nano sphere, in particular to a preparation method of a protein magnetic imprinting nano sphere which takes one of hemoglobin, muramidase or serum protein as template molecules; the preparation method includes the following steps: synthesizing magnetic nano particles which are Fe3O4 nano particles covered with silicon dioxide on the surfaces; carrying out silanization to the amino-groups on the surface of the magnetic sphere; using glutaric dialdehyde to connect protein; using silylation agent to fix the space structure of template protein; alkaline eluting the protein on the surface of the magnetic sphere to form imprinting sites. The hemoglobin, muramidase or serum protein magnetic nano imprinting polymer sphere prepared by the invention combines the precise and specific identification property of molecular imprinting and the quick separation property of the magnetic nano sphere under the action of an external magnetic field, integrates the advantages of molecular imprinting and the magnetic nano sphere, avoids complex centrifugation operation, plays vital roles in the separation of cells, protein and nucleic acid, the detection of biomolecules, tumor diagnosis and medicine targeting therapy and has promising application prospect in the field of isolation analysis.

The invention relates to the use of Fused Deposition Modeling to construct three-dimensional (3D) bioresorbable scaffolds from bioresorbable polymers such as polycaprolactone (PCL), or from composites of bioresorbable polymers and ceramics, such as polycaprolactone/hydroxyapatite (PCL/HA). Incorporation of a bioresorbable ceramic to produce a hybrid/composite material support provides the desired degradation and resorption kinetics. Such a composite material improves the biocompatibility and hard tissue integration and allows for increased initial flash spread of serum proteins. The basic resorption products of the composite also avoids the formation of an unfavorable environment for hard tissue cells due to a decreased pH. The scaffolds have applications in tissue engineering, e.g., in tissue engineering bone and cartilage.

The invention discloses an ECL (electrochemiluminescence) immunosensor for detecting tumor markers and a preparation method and applications thereof. The immunosensor comprises a working electrode, a reference electrode and a counter electrode, wherein the working electrode is a gold electrode, cysteamine, glutaraldehyde, a tumor marker first-antibody, a tumor marker, and a composite functionalized nanosphere are sequentially decorated on the surface of the gold electrode, the composite functionalized nanosphere is simultaneously marked by a tumor marker second-antibody and an ECL marker, and non-specific active sites are closed by using bovine serum albumins. The preparation method comprises the steps of preparing the gold electrode on which the tumor marker first-antibody is fixedly carried; synthesizing the composite functionalized nanosphere simultaneously marked by the tumor marker second-antibody and the ECL marker; and finally, assembling the obtained gold electrode and the composite functionalized nanosphere into an ECL immunosensor. The ECL immunosensor disclosed by the invention is high in sensitivity, rapid in analysis speed, strong in stability and selectivity, good in reproducibility, easy to operate, and flexible in method.

The invention discloses a rudimental immune antibody which is used to detect organic phosphorus pesticide residue and its application, the character of the invention is using diethyl phosphonic acid acetic acid as hapten, produce artificial immunogen through coupling with bovine serum albumin(BSA), and produce several clone antibody through immune Zelanian giant blanc or produce mono clone antibody through chmice immune, cell amalgamation, filtration, clone planting and other steps, the several and single antibody can be used to indirect emulative ELISA, direct ELISA, or immune test paper to detect the rudimental phosphorus pesticide. The excellences of the invention including: the selected hapten has several organic phosphorus pesticides general structure, the structure reforming is not necessary, it can immune animal after coupling with protein, it can also be used to detect organic phosphorus pesticide in food and water source, this show the rapid and convenient of the immune detecting tehchnology.

The present invention discloses twenty two 22 protein biomarkers of breast cancer. More specifically, the present invention discloses the identities, specificities, and uses of up to twenty two (22) protein biomarkers in blood serum for distinguishing between patients with earlier and later stages of breast cancer, patients with benign breast diseases or abnormalities, and normal individuals lacking breast abnormalities. More specifically, the present invention relates to specificities of isoforms of up to 22 protein biomarkers in blood serum for distinguishing between patients with earlier and later stages of breast cancer, patients with benign breast diseases or abnormalities, and normal individuals lacking breast abnormalities.

The invention discloses a preparation method of a high-flux PVDF porous membrane. The method comprises the following steps: mixing PVDF, a highly hydrophilic polymer, a pore-forming additive, deionized water, a solvent and graphene powder, curing, stirring, standing, defoaming so as to obtain membrane casting liquid, and forming a wet membrane from the membrane casting liquid in a scraping manner; pre-evaporating the wet membrane in air, putting the pre-evaporated membrane in a solidification bath, and soaking to obtain a primary membrane in the deionized water; putting the primary membrane in the deionized water, performing heating activation, soaking in absolute ethyl alcohol and n-butyl alcohol, and airing in the air. According to the method, graphene nano-particles with two-dimensional structures are used as additives, the pure water flux can be up to 800L*m<-2>*h<-1> or more, and the rejection rate on bovine serum albumin is 98% or more; the hydrophilic polymer is added for performing the activation on the primary membrane, so that the hydrophilia of the PVDF membrane is greatly improved, and the membrane surface contact angle is up to 59.8 degrees; a porous membrane material is adopted, so that the structure is controllable, and the pore diameter range is controlled to be within 0.1-5 microns.

The present invention provides a sustained-release composition by which a sustained-release effect can be obtained for a long time when injecting microparticles of the composition in an amount that can be subcutaneously or intramuscularly injected to a human with ease and without pain. The composition comprises porous hydroxyapatite microparticles having pores embolized by filling the pores in the microparticles with a biologically active drug, a human serum protein, and a mucopolysaccharide, and adding a divalent metal ion. Alternatively, the composition comprises porous hydroxyapatite microparticles having pores embolized in the outer layer by filling the pores in the microparticles with a biologically active drug, a human serum protein, and a water-soluble calcium salt one after another or at one time, and then adding sodium carbonate, sodium hydrogen carbonate, or an aqueous carbonate ion solution.

The invention discloses an endotoxin adsorbent using a molecular cluster as a functional group and a preparation method thereof, and belongs to the fields of bioseparation and biomedical engineering. By taking agarose gel as a vector, the endotoxin adsorbent is subjected to epoxy activation to be directly coupled with a molecular sieve frame epsilon-polylysine or polyaspartic acid, then the coupled mixture is ingrafted with micromolecular lysine or lycine by virtue of a condensation reaction to prepare the adsorbent. The adsorbent prepared by the method has higher removal rate to endotoxin inserum of a human, but adsorbs less serum protein. Meanwhile, the preparation process of the adsorbent has the advantages of mild conditions, fewer synthesis steps and relatively low material cost.

The invention discloses a method for extracting and purifying calf serum protein-removing extract, which comprises extracting calf venous blood, separating plasma, removing protein with ethanol, removing ethanol through decompression, charging composite proteolytic enzyme, subjecting supernatant fluid to ultrafiltration, desalinizing ultrafiltrate with gluglucosan G-15 gel chromatography, collecting elution portion with specific absorption at 280nm, then separating with DEAE-Sephadex-50 gel chromatography, collecting elution portion with specific absorption at a second 280nm, then carrying out virus deactivation by means of microporous membrane filtration and ultraviolet irradiation.

The invention discloses a fluorescent quantitative test paper strip for simultaneously detecting algal toxins MC-LR/RR/YR in a water body and a preparation method and application of the fluorescent quantitative test paper strip. The preparation method comprises the following steps: firstly, marking specific antibodies and rabbit IgG of three algal toxins by using fluorescent microspheres, and drying the three algal toxins on a fluorescent combining pad; sequentially drawing detection lines T1, T2 and T3 of conjugate of the three algal toxins and bovine serum protein and a goat anti-rabbit quality control line C on an NC membrane; finally assembling the test paper strip, namely, sequentially lapping and adhering a sample pad, a fluorescent marker conjugate pad, a nitrocellulose membrane with the three detection lines (T1, T2 and T3 lines) and one quality control line (line C), and a piece of water absorbing paper to a PVC hard board, after the components are assembled, shearing so as to obtain the test paper strip, and finally packaging the test paper strip in a plastic shell. The detection sensitivity on the three algal toxins, of the test paper strip disclosed by the invention, is up to 0.05ng/ml, the quantitative linear range of the test paper strip is 0.1-10ng/ml, the sample needs no pretreatment, the detection time is only 6 minutes, and rapid quantitative detection on the three common algal toxins in water bodies can be achieved, so that the test paper strip has very high practical values.

The invention relates to a medical reagent, in particular to a kit for determining glycated serum protein, which comprises a reagent R1 and a reagent R2, wherein the reagent R1 contains buffer solution of 20mmol/L, surfactants accounting for 0.5 percent of the reagent R1, anti-interference substances of 0.05-0.1mmol/L, stabilizers of 0.5-1g/L, and preservatives of 0.05g/L. The reagent R2 contains fructosyl amino acid oxidase of 20mmol/L, horseradish peroxidase of 20KU/L, chromogen of 0.1mmol/L, preservatives of 0.05g/L and stabilizers of 0.5-1g/L. Compared with the prior art, when the kit for determining glycated serum protein is used, the glycated serum protein can be determined in an enzymatic method, the HPLC (high performance liquid chromatography) can be completely substituted, and the kit can be applied to clinical laboratories for determination of large bulk samples and can be operated easily. Moreover, the kit has a wide linear scope and high value of application, and the cost of the kit is low.

The invention discloses a polymer film with antifouling and anti-bacterial functions and a preparation method of the polymer film. Silver-containing nano particles are uniformly dispersed in the polymer film, and the surfaces of the silver-containing nano particles are coated with silver ions through chemical bonds. The adsorption amount of the polymer film to bovine serum albumin in unit area is 10 micrograms per square centimeter below, and the secondary water flux recovery rate of the separation film reaches 95% above. The kill rate of the polymer film for escherichia coli, staphylococcus aureus, pseudomonas aeruginosa, candida albicans and yeast is 100%.

A conjugate of norfloxacin is prepared from norfloxacin semi-antigen and the bovine serum albumin (or egg albumin) as the carrier able to generate immunogenicity through coupling. It can be used for preparing the reagent kit for the enzyme-linked immunoassay of norfloxacin.

The invention belongs to the field of biology and medicine examination, and relates to a method for a protein spectrum of differential expression in a type 2 diabetes serum sample. The method comprises the following steps: adopting a surface-enhanced laser desorption/ionization time-of-flight mass-spectrometric technique to screen whole protein fingerprint of a diabetes chronic complication serum sample, using a data mining technique to screen biological labels in the fingerprint, establishing an analytic decision tree model of N serum protein components, and displaying that the type 2 diabetic nephropathy patient has the difference of the serum protein fingerprint as a result through blind verification and enlarged sample verification models. The method possibly provides reference information for further diagnosis and pathogenesis of diabetic nephropathy, provides research basis and new target for studying molecular mechanism formed by the diabetic nephropathy, and can further be used for guiding drug development and curative effect analysis.

The invention discloses a label-free electrochemical immunosensor for melamine content determination, and a preparation method and application thereof. The immunosensor comprises a substrate electrode, wherein the surface of the substrate electrode is modified by a graphene-melamine-chitosan composite, and nonspecific active sites are sealed by bovine serum proteins. The method for preparing the electrochemical immunosensor is implemented by fixing melamine antigens on the surface of a glass carbon electrode with graphene/chitosan composite materials. Based on an immunoreactive competition mode, the electrochemical immunosensor monitors immune reaction through cyclic voltammetry and differential pulse voltammetry by taking K3Fe(CN)6 as a probe,, and can be used for melamine content detection. The immunosensor disclosed by the invention is high in sensitivity and specificity, simple in detection method and wide in application range; the limit of detection can reach 0.2 ng/ml, and the linear range is 5-1500 ng/ml; and the immunosensor has the characteristics of high speed, high efficiency, high sensitivity, good specificity, simple operation, low cost and the like.

The invention relates to a preparation method of a fluorescent molecular probe for detecting fluoride ions in aqueous solutions through fluorescence enhancement and an application of the fluorescent molecular probe to detecting fluoride ions. The fluorescent molecular probe is prepared by protecting 1,4-diethyl-1,2,3,4-tetrahydro-7-hydroxyquinoxaline-6-aldehyde taken as a raw material with silane and then condensing the raw material and malononitrile. The fluorescent molecular probe is simple and convenient to synthesize, and reaction conditions are mild. The fluorescent molecular probe has the specific characteristics that the probe molecule has stable optical properties and higher synthetic yield; the probe molecule has high sensitivity of detection of fluoride ions in the aqueous solutions and low lower limit of detection, and the limit of detection is 5.4mu M; the response range is 0-1mM and the detection range is wide; the probe molecule has good selectivity and has no responses to anions, such as chloride ions, bromide ions, iodide ions, tetrabutylammonium cyanide, nitrates radicals, hydrosulfate radicals, perchlorate radicals, acetate radicals, thiocyanate radicals, azide radicals, cysteine, bovine serum albumin, carbonate radicals, sulfate radicals and reduced glutathione; the fluorescent molecular probe has practical application values in the fields of biochemistry, environmental sciences and the like.

The present invention relates to isolated protein sequences that correspond to cell binding peptides, fragments, neo-structures and/or neo-epitopes of a normally occurring serum protein present in human tissue, wherein the peptide, fragment, neo-structure and/or neo-epitope has an immunoregulatory activity and is the result of either an enhanced proteolytic activity and/or conformational changes in a tissue, or a malignant tumour. In the present patent application, a common structure of several of these peptides, fragments, neo-structures and/or neo-epitopes, having immunoregulatory activity by binding to receptors on immune cells, has been identified. The present invention further also relates to monoclonal and/or polyclonal antibodies directed to a cell binding fragment of a normally occurring serum protein present in human tissue, as described above.